Sigma-Aldrich®
Lab & Production Materials

MilliporeSigma

Cell Marque™ Tissue Diagnostics

PRAME (EP461)

Rabbit Monoclonal Antibody

PRAME (PReferentially-expressed Antigen in MElanoma) is a gene encoded on the 22q11-22 chromosomal sequence and encodes a 509 amino acid residue protein.[1] PRAME is a melanoma antigen that is preferentially expressed in tumors and is recognized by cytotoxic T lymphocytes.[2,3] PRAME can be used to distinguish between malignant melanoma cells and nevus cells,[4] and therefore may be useful for diagnostic purposes to support a suspected case of melanoma. PRAME is considered a cancer-testis antigen (CTA)[5] and is not strongly expressed in most other normal tissues. PRAME is positively expressed in about half of uveal melanomas,[6] and the majority of mucosal melanomas.[7]



Skin Melanoma



Melanoma



Benign Nevus

Ordering Information

Description	Cat No.
0.1 mL concentrate	**484R-14**
0.5 mL concentrate	**484R-15**
1.0 mL concentrate	**484R-16**
1.0 mL predilute	**484R-17**
7.0 mL predilute	**484R-18**
25 mL predilute	**484R-10**

Intended Use:

The product herein is intended for laboratory use in the detection of PRAME in formalin-fixed, paraffin-embedded tissue stained in qualitative immunohistochemistry (IHC) testing. This product is not a stand-alone diagnostic, and cannot be used for diagnosis, treatment, prevention, or mitigation of disease.

Product Information:

Visualization: Nuclear
Controls: Melanoma
Dilution Range: 1:25–1:50
Associated Specialty: Dermatopathology

CELL MARQUE
RabMAb®
Technology from Abcam

References:

1. Wadelin, Frances et al. "Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia." Molecular cancer vol. 9 226. 27 Aug. 2010, doi:10.1186/1476-4598-9-226
2. Lezcano, Cecilia et al. "PRAME Expression in Melanocytic Tumors." The American journal of surgical pathology vol. 42,11 (2018): 1456-1465. doi:10.1097/PAS.0000000000001134
3. Ikeda, H et al. "Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor." Immunity vol. 6,2 (1997): 199-208. doi:10.1016/s1074-7613(00)80426-4
4. Lezcano, Cecilia et al. "Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma." The American journal of surgical pathology vol. 44,4 (2020): 503-508. doi:10.1097/PAS.0000000000001393
5. Zhang, Wa et al. "PRAME expression and promoter hypomethylation in epithelial ovarian cancer." Oncotarget vol. 7,29 (2016): 45352-45369. doi:10.18632/oncotarget.9977
6. Gezgin, Gulcin et al. "PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma." JAMA ophthalmology vol. 135,6 (2017): 541-549. doi:10.1001/jamaophthalmol.2017.0729
7. Toyama, Aimi et al. "Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. 32,12 (2019): 1727-1733. doi:10.1038/s41379-019-0335-4

USA
Toll Free: **800.665.7284**
Phone: **916.746.8900**
Fax: **916.746.8989**
Email: **service@cellmarque.com**
www.cellmarque.com

CANADA
Phone: **+1 916.746.8900**
Fax: **+1 916.746.8989**
Email: **international@cellmarque.com**
www.cellmarque.com

MilliporeSigma
400 Summit Drive
Burlington, MA 01803

SigmaAldrich.com

MS_FL7982EN Ver. 1.1 36432 05/2021